MITI-101 / MindImmune - LARVOL DELTA

MindImmune…announced a transformative $5 million award from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of its lead therapeutic candidate, MITI-101 - a first-in-class program designed to target immune pathways driving neuroinflammation and neurodegeneration in Alzheimer’s disease (Businesswire) - "This investment will support completion of critical translational studies and IND submission, as well as strategic planning for early clinical development."

Financing • Alzheimer's Disease

Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune’s Lead Alzheimer’s Prevention Program, MITI-101 (PRNewswire) - "Under the agreement, Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing services via its ModularCMC platform specializing in antibody-based modalities to support the advancement of the MITI-101 program, MindImmune's lead monoclonal antibody (mAb) program under development for the treatment of Alzheimer's disease."

Licensing / partnership • Alzheimer's Disease